
Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Podcasting since 2020 • 1069 episodes
Surfing the MASH Tsunami
Latest Episodes
S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism
This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger G...
•
Season 6
•
Episode 13
•
37:13

S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease
Last month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially de...
•
Season 6
•
Episode 13
•
20:19

S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management
This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger G...
•
Season 6
•
Episode 13
•
19:48

S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health
00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discu...
•
Season 6
•
Episode 13
•
1:13:53

S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologi...
•
Season 6
•
Episode 12
•
21:39
